ADAR1-dependent miR-3144-3p editing simultaneously induces MSI2 expression and suppresses SLC38A4 expression in liver cancer
2
조회
0
다운로드
2
인용
0
참고문헌
초록
Aberrant adenosine-to-inosine (A-to-I) RNA editing, catalyzed by adenosine deaminase acting on double-stranded RNA (ADAR), has been implicated in various cancers, but the mechanisms by which microRNA (miRNA) editing contributes to cancer development are largely unknown. Our multistage hepatocellular carcinogenesis transcriptome data analyses, together with publicly available data, indicated that ADAR1 was the most profoundly dysregulated gene among RNA-editing enzyme family members in liver cancer. Targeted inactivation of ADAR1 inhibited the in vitro tumorigenesis of liver cancer cells. An integrative computational analyses of RNA-edited hotspots and the known editing frequency of miRNAs suggested that the miRNA miR-3144-3p was edited by ADAR1 during liver cancer progression. Specifically, ADAR1 promoted A-to-I editing of canonical miR-3144-3p to replace the adenosine at Position 3 in the seed region with a guanine (ED_miR-3144-3p(3_A < G)) in liver cancer cells. We then demonstrated that Musashi RNA-binding protein 2 (MSI2) was a specific target of miR-3144-3p and that MSI2 overexpression was due to excessive ADAR1-dependent over-editing of canonical miR-3144-3p in liver cancer. In addition, target prediction analyses and validation experiments identified solute carrier family 38 member 4 (SLC38A4) as a specific gene target of ED_miR-3144-3p(3_A < G). The ectopic expression of both ADAR1 and the ED_miR-3144-3p(3_A < G) mimic enhanced mitotic activities, and ADAR1 suppressed SLC38A4 expression in liver cancer cells. Treatments with mouse-specific ADAR1-, MSI2-siRNA-, or SLC38A4-expressing plasmids suppressed tumorigenesis and tumor growth in a mouse model of spontaneous liver cancer. Our findings suggest that the aberrant regulation of ADAR1 augments oncogenic MSI2 effects by excessively editing canonical miR-3144-3p and that the resultant ED_miR-3144-3p(3_A < G) simultaneously suppresses tumor suppressor SLC38A4 expression, contributing to hepatocellular carcinogenesis.
Abstract
Aberrant adenosine-to-inosine (A-to-I) RNA editing, catalyzed by adenosine deaminase acting on double-stranded RNA (ADAR), has been implicated in various cancers, but the mechanisms by which microRNA (miRNA) editing contributes to cancer development are largely unknown. Our multistage hepatocellular carcinogenesis transcriptome data analyses, together with publicly available data, indicated that ADAR1 was the most profoundly dysregulated gene among RNA-editing enzyme family members in liver cancer. Targeted inactivation of ADAR1 inhibited the in vitro tumorigenesis of liver cancer cells. An integrative computational analyses of RNA-edited hotspots and the known editing frequency of miRNAs suggested that the miRNA miR-3144-3p was edited by ADAR1 during liver cancer progression. Specifically, ADAR1 promoted A-to-I editing of canonical miR-3144-3p to replace the adenosine at Position 3 in the seed region with a guanine (ED_miR-3144-3p(3_A < G)) in liver cancer cells. We then demonstrated that Musashi RNA-binding protein 2 (MSI2) was a specific target of miR-3144-3p and that MSI2 overexpression was due to excessive ADAR1-dependent over-editing of canonical miR-3144-3p in liver cancer. In addition, target prediction analyses and validation experiments identified solute carrier family 38 member 4 (SLC38A4) as a specific gene target of ED_miR-3144-3p(3_A < G). The ectopic expression of both ADAR1 and the ED_miR-3144-3p(3_A < G) mimic enhanced mitotic activities, and ADAR1 suppressed SLC38A4 expression in liver cancer cells. Treatments with mouse-specific ADAR1-, MSI2-siRNA-, or SLC38A4-expressing plasmids suppressed tumorigenesis and tumor growth in a mouse model of spontaneous liver cancer. Our findings suggest that the aberrant regulation of ADAR1 augments oncogenic MSI2 effects by excessively editing canonical miR-3144-3p and that the resultant ED_miR-3144-3p(3_A < G) simultaneously suppresses tumor suppressor SLC38A4 expression, contributing to hepatocellular carcinogenesis.
참고문헌 (23)
- Keegan, L. P., "The many roles of an RNA editor", Nat. Rev. Genet, 2, pp.869~878 (2001)
- Bass, B. L., "RNA editing by adenosine deaminases that act on RNA", Annu. Rev. Biochem, 71, pp.817~846 (2002)
- Avesson, L., "The emerging role of RNA and DNA editing in cancer", Biochim. Biophys. Acta, 1845, pp.308~316 (2014)
- Tan, M. H., "Dynamic landscape and regulation of RNA editing in mammals", Nature, 550, pp.249~254 (2017)
- Han, L., "The genomic landscape and clinical relevance of A-to-I RNA editing in human cancers", Cancer Cell, 28, pp.515~528 (2015)
- Baysal, B. E., "RNA editing in pathogenesis of cancer", Cancer Res, 77, pp.3733~3739 (2017)
- Wang, Y., "Systematic characterization of A-to-I RNA editing hotspots in microRNAs across human cancers", Genome Res, 27, pp.1112~1125 (2017)
- Ha, M., "Regulation of microRNA biogenesis", Nat. Rev. Mol. Cell. Biol, 15, pp.509~524 (2014)
- Negi, V., "Altered expression and editing of miRNA-100 regulates iTreg differentiation", Nucleic Acids Res, 43, pp.8057~8065 (2015)
- Shoshan, E., "Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis", Nat. Cell. Biol, 17, pp.311~321 (2015)
- Ramirez-Moya, J., "ADAR1-mediated RNA editing is a novel oncogenic process in thyroid cancer and regulates miR-200activity", Oncogene, 39, pp.3738~3753 (2020)
- Chen, L., "Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma", Nat. Med, 19, pp.209~216 (2013)
- Wang, A. G., "Gender-dependent hepatic alterations in H-ras12V transgenic mice", J. Hepatol, 43, pp.836~844 (2005)
- Futschik, M. E., "Noise-robust soft clustering of gene expression timecourse data", J. Bioinform. Comput. Biol, 3, pp.965~988 (2005)
- Bazak, L., "A-to-I RNA editing occurs at over a hundred million genomic sites, located in a majority of human genes", Genome Res, 24, pp.365~376 (2014)
- Shen, Q., "Barrier to autointegration factor 1, procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3, and splicing factor 3b subunit 4 as early-stage cancer decision markers and drivers of hepatocellular carcinoma", Hepatology, 67, pp.1360~1377 (2018)
- Chan, T. H., "A disrupted RNA editing balance mediated by ADARs(Adenosine DeAminases that act on RNA)in human hepatocellular carcinoma", Gut, 63, pp.832~843 (2014)
- Kudinov, A. E., "Musashi RNA-binding proteins as cancer drivers and novel therapeutic targets", Clin. Cancer Res, 23, pp.2143~2153 (2017)
- Torsin, L. I., "Editing and chemical modifications on non-coding RNAs in cancer : a new tale with clinical significance", Int. J. Mol. Sci, 22, pp.581~ (2021)
- Nemlich, Y., "MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth", J. Clin. Invest, 123, pp.2703~2718 (2013)
- Wojcicka, A., "Next generation sequencing reveals microRNA isoforms in liver cirrhosis and hepatocellular carcinoma", Int. J. Biochem. Cell. Biol, 53, pp.208~217 (2014)
- Shi, Q., "Membrane topological structure of neutral system N", A amino acid transporter 4(SNAT4)protein, 2011, pp.286, 38086~38094
- Li, J., "SLC38A4 functions as a tumour suppressor in hepatocellular carcinoma through modulating Wnt", beta-catenin, HMGCS2 axis, pp.Br. J. Cancer, 2021[DOI]